|
1 Indications And Usage 1 Indications And Usage Synagis Is Indicated For The Prevention Of Serious Lower Respiratory Tract Disease Caused By Respiratory Syncytial Virus (Rsv) In Pediatric Patients: • With A History Of Premature Birth (Less Than Or Equal To 35 Weeks Gestational Age) And Who Are 6 Months Of Age Or Younger At The Beginning Of Rsv Season, • With Bronchopulmonary Dysplasia (Bpd) That Required Medical Treatment Within The Previous 6 Months And Who Are 24 Months Of Age Or Younger At The Beginning Of Rsv Season, • With Hemodynamically Significant Congenital Heart Disease (Chd) And Who Are 24 Months Of Age Or Younger At The Beginning Of Rsv Season [See Clinical Studies (14) ] . Limitations Of Use: The Safety And Efficacy Of Synagis Have Not Been Established For Treatment Of Rsv Disease [See Warnings And Precautions (5.4) ] . Synagis Is A Respiratory Syncytial Virus (Rsv) F Protein Inhibitor Monoclonal Antibody Indicated For The Prevention Of Serious Lower Respiratory Tract Disease Caused By Respiratory Syncytial Virus (Rsv) In Pediatric Patients: • With A History Of Premature Birth (Less Than Or Equal To 35 Weeks Gestational Age) And Who Are 6 Months Of Age Or Younger At The Beginning Of Rsv Season, • With Bronchopulmonary Dysplasia (Bpd) That Required Medical Treatment Within The Previous 6 Months And Who Are 24 Months Of Age Or Younger At The Beginning Of Rsv Season, • With Hemodynamically Significant Congenital Heart Disease (Chd) And Who Are 24 Months Of Age Or Younger At The Beginning Of Rsv Season. Limitations Of Use: The Safety And Efficacy Of Synagis Have Not Been Established For Treatment Of Rsv Disease. (1)
|